Clinical Trial

Impact of Semaglutide on Tobacco Use and Related Health Behaviors

Study acronym: ONSET
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This pilot randomized trial will assess the impact of 12 weeks of semaglutide administration (vs placebo) on changes in: (i) tobacco use and related factors (nicotine craving, withdrawal, motivation to quit, etc.) and (ii) biological biomarkers of health (e.g., epigenetics, glucose variability via continuous glucose monitoring \[CGM\], etc.) in adult smokers with obesity (n = 40). We will integrate molecular biology procedures (e.g., epigenetics) to maximize internal validity with real-world smartphone-based ecological momentary assessment (EMA) surveys to maximize external validity
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-20.
Trial Details
NCT Number NCT06986993
Lead Sponsor University of Oklahoma
Conditions Tobacco Use
Enrollment 40 participants
Start Date 2024-07-01
Primary Completion 2028-05-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-27